initi outperform pt
im one w/
sign stabil base strength lead growth recoveri
decidedli neg rx suppli chain much
avoid share premis market incorrectli
discount degre ep de-rat come industri macro
fundament final show sign stabil number co-
specif factor like influenc growth higher return
share construct highlight fact gener deflat
independ price worsen least month
cite util continu tepid gener stabl
pace coupl moder intern invest on-
board integr hd smith continu growth
mwi specialti see growth reacceler loom look oi
growth return ep approach double-digit
coupl attract yield offer investor
hd smith solid tuck-in deploy upsid exist post reform
furthermor see upsid option tax reform us
well continu bia toward capit return leverag remain
manag even recent tuck-in deal would also note
realli like recent hd smith deal small like
offer attract return vs recent
growth bias thu see abc current discount
attract entri point vs histor rang contend
also fit within macro framework valu revers given
dynam see risk reward favor thu initi share
o/p rate
thing watch tone gener drug price omx trajectori
debat inflationari environ new normal
opex leverag exist post recent invest ramp
management focu return capit vs growth
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average price-to-earnings
basi translat vs average
downsid risk potenti resumpt independ
price war result materi margin degrad signific profit
pressur signific downtick sell-sid gener deflat without
similar movement buy side margin result overal compress
increment soft pharmedium growth lessen inflat
continu challeng relat revamp qc process polit
threat chang rx price methodolog gross net intens
scrutini opioid curtail distribut profit execut challeng
onboard hd smith asset potenti leakag key independ
custom transit period inabl transit
specialti contract long term new econom allow fair payment
differenti servic
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi outperform pt
im one w/
last page report import disclosur regard stock report
tabl content
debat inflationari environ new normal
debat management focu return capit vs growth
financi model path growth re-norm
point differenti vs st
iv valuat risk inflat pictur stabil
 conclus initi outperform prevail
bet big share gain growth diversif
abc stock peak gener inflat boom
newli expand anim health via mwi
thesi stabil macro driver drug complex
yield superior growth given specialti hd smith
vet busi play investor
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk resumpt hyper-deflationari
environ coupl independ price
esrx make almost half abc revenu
stabl manag team transform busi
ex esrx
elect chairman
join compani svp
previous vice-president corpor control sinc
join compani
prior serv vice-president financ syncor
previous serv evp global sourc
manufactur relat
founder lash group
debat inflationari environ new normal
expect jan brand inflat in-lin monitor close
work market growth suggest revenu
suppli chain expand lsd-msd
rate inflat sensit factor notabl
enter inflat level earli jan serv
crucial point data better understand
pharma behavior
last januari came somewhat modest relief
vs investor worri hsd brand
inflat msd gener deflat
close watch commentari
price increas track understand one
mani variabl influenc firm suppli chain
o/p convers return histor level
interest look group op/gp
convers depict spike
relat hyperinfl
gener specialti
op/gp pick tradit
gener deflat stabil depress level
number hyperinfl buy side
number hyperinfl sell side
forese inflat trajectori stabil lesser level translat favor profit outlook
invest redefin custom experi
go forward capital-expenditure normal lower level
commit reorgan
strateg invest revamp dc
shift autom help yield organiz
benefit effici time addit
prepar onboard volum
front compani activ
invest build new robust technolog
platform better support lash group patient servic
also order customer-ord entri fusion
patient support system logist system
abc autom network includ five
seven new dc expect bring last two
on-line end year total dc
opex trend relat manag new dc
howev ramp depress averag om
underli op leverag improv mix also depress impact report om
debat management focu return capit vs growth
acquisit hd smith
purchas bn
purchas bn
hsd ldd revenu
growth help off-set
pharma
expect slow
msd due
cash roi
expect increas repurchas activ time
novemb announc acquisit
 smith largest independ wholesal
center across
subsidiari triplefin acret
includ transact
paid mm cash
acquisit expect slightli
accret ep
expect revenue growth op incom
pharma ds op growth
deal expect close earli
buy hd smith
hd bring higher-margin independ
pharmaci histor
abc larger scale improv gener
sourc like largest sourc cost synergi
acquisit also fill geograph hole
histor horizont bolt-on solid
return pattern hd smith seem like continu
model summari point differenti vs street
swing factor cadenc drug inflat specialti rx growth potenti benefit tax reform
point
peer given share
om pressur
mix despit better
forecast st
market impli
million except per share data fy end septemb organ gp growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount januari
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate vs prior reform
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total fine hd smith total valu valu per perpetu growth valu enterpris enterpris valu januari
valuat trend notabl lower inflat relat fear
metric final found stabil albeit histor level w/ room upsid growth normal
risk point favor risk reward profil resumpt materi deflat independ pressur unlik
potenti resumpt independ price war result materi margin degrad signific profit pressur
signific downtick sell-sid gener deflat without similar movement buy side margin result overal compress
increment soft pharmedium growth lessen inflat continu challeng relat revamp qc process
polit threat chang rx price methodolog gross net intens scrutini opioid curtail distribut profit
execut challeng onboard hd smith asset potenti leakag key independ custom transit period
inabl transit specialti contract long term new econom allow fair payment differenti servic
conclus initi outperform pt upsid
favor share return thesi hd smith specialti stabl inflat reacceler
decidedli neg rx suppli chain much avoid share
premis market incorrectli discount degre ep de-rat come
industri macro fundament final show sign stabil number co-
specif factor like influenc growth higher return share construct
highlight fact gener deflat independ price worsen
least month cite util continu tepid gener stabl pace
coupl moder intern invest on-board integr
hd smith continu growth mwi specialti see growth reacceler loom
look oi growth return ep approach double-digit
coupl attract yield offer investor reason risk reward
furthermor see upsid option tax reform us well continu
bia toward capit return leverag remain manag even recent tuck-in deal
would also note realli like recent hd smith deal small
like offer attract return vs recent growth bias
thu see abc current discount attract entri point vs
histor rang contend also fit within macro framework valu revers
given dynam see risk reward favor thu initi share o/p rate
thing watch tone gener drug price omx trajectori revenu growth
pleas feel free reach question follow-up
medic suppli devic
valuat price target base dcf methodolog contempl wacc termin
ebitda multipl equat perpetu growth rate pt translat ebitda vs
average price-to-earnings basi translat vs average
downsid risk potenti resumpt independ price war result materi margin degrad signific
profit pressur signific downtick sell-sid gener deflat without similar movement buy side margin result overal
compress increment soft pharmedium growth lessen inflat continu challeng relat revamp
qc process polit threat chang rx price methodolog gross net intens scrutini opioid curtail
distribut profit execut challeng onboard hd smith asset potenti leakag key independ custom
transit period inabl transit specialti contract long term new econom allow fair payment
articl articl
time dissemin januari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
